[1] HARDING C M,HENNON S W,FELDMAN M F. Uncovering the mechanisms of Acinetobacter baumannii virulence[J]. Nat Rev Mi-crobiol,2018,16( 2):91-102.
[2] WORLD HEALTH ORGANIZATION. Guidelines for the prevention and control of carbapenem-resistant enterobacteriaceae,Acineto-bacter baumannii and pseudomonas aeruginosa in health care facili-ties[R]. Gevena:WHO,2017:1-76.
[3] 胡付品,郭燕,周德妹,等. 2021年CHINET中国细菌耐药监测[J].中国感染与化疗杂志,2022,22( 5):521-530.
[4] CHEN W. Host-pathogen interactions in Acinetobacter baumannii infection:recent advances and future challenges[J]. Future Microbi-ol,2020,15:841-845.
[5] MORRIS F C,DEXTER C,KOSTOULIAS X,et al. The mechanisms ofdiseasecausedbyAcinetobacterbaumannii[J].FrontMicrobiol,2019, 10:1601.
[6] 陈佰义,何礼贤,胡必杰,等.中国鲍曼不动杆菌感染诊治与防控专家共识[J].中华医学杂志,2012( 2):76-85.
[7] 孙康,潘蕾,金发光.多重耐药鲍曼不动杆菌肺炎治疗进展[J].中华结核和呼吸杂志,2021,44( 6):582-587.
[8] FOULDS J,CHAI T J. Defeat of colicin tolerance in Escherichia coli ompA mutants:evidence for interaction between colicin L-JF246 and the cytoplasmic membrane[J]. J Bacteriol,1978,133( 1):158-164.
[9] TIKU V,KOFOED E M,YAN D,et al. Outer membrane vesicles containing OmpA induce mitochondrial fragmentation to promote pathogenesisofAcinetobacter baumannii[J].SciRep,2021,11(1):618.
[10] NIE D,HU Y,CHEN Z,et al. Outer membrane protein A(OmpA)as a potential therapeutic target for Acinetobacter baumannii infection [J]. J Biomed Sci,2020,27( 1):26.
[11] MUHAMMAD M H,IDRIS A L,FAN X,et al. Beyond risk:bacterial biofilms and their regulating approaches[J]. Front Microbiol,2020, 11:928.
[12] BROSSARD K A,CAMPAGNARI A A. The Acinetobacter bauman-nii biofilm-associated protein plays a role in adherence to human epithelial cells[J]. Infect Immun,2012,80( 1):228-233.
[13] BATEMAN T J,SHAH M,HO T P,et al. A Slam-dependent hemophore contributes to heme acquisition in the bacterial pathogen Acinetobacter baumannii[J]. Nat Commun,2021,12( 1):6270.
[14] GIARDINA B J,SHAHZAD S,HUANG W,et al. Heme uptake and utilization by hypervirulent Acinetobacter baumannii LAC-4 is de-pendent on a canonical heme oxygenase(abHemO)[J]. Arch Biochem Biophys,2019,672:108066.
[15] SAIPRIYA K,SWATHI C H,RATNAKAR K S,et al. Quorum-sens-ing system in Acinetobacter baumannii:a potential target for new drug development[J]. J Appl Microbiol,2020,128( 1):15-27.
[16] STACY D M,WELSH M A,RATHER P N,et al. Attenuation of quo-rum sensing in the pathogen Acinetobacter baumannii using non-native N-Acyl homoserine lactones[J]. ACS Chem Biol,2012,7(10):1719-1728.
[17] KONGTHAI P,THUMMEEPAK R,LEUNGTONGKAM U,et al. In-sight into molecular epidemiology,antimicrobial resistance,and vir-ulence genes of extensively drug-resistant Acinetobacter baumannii in Thailand[J]. Microb Drug Resist,2021,27( 3):350-359.
[18] YANG C H,SU P W,MOI S H,et al. Biofilm formation in Acineto-bacter baumannii:genotype-phenotype correlation [J]. Molecules, 2019,24( 10):1849.
[19] MELLMAN I. Dendritic cells:master regulators of the immune re-sponse[J]. Cancer Immunol Res,2013,1( 3):145-149.
[20] ABDI H A,HORMOZI B,NAJIMI M,et al. High prevalence of iron acquisition genes among Acinetobacter baumannii strains isolated from patients with urinary tract infections in southeast of Iran [J]. Avicenna J Clin Microbiol Infect,2015,2( 4):30656-30656.
[21] PORBARAN M,TAHMASEBI H,ARABESTANI M. A Comprehen-sive study of the relationship between the production of β-lactamase enzymes and iron/siderophore uptake regulatory genes in clinical isolates of Acinetobacter baumannii[J]. Int J Microbiol,2021,2021:5565537.
[22] THUMMEEPAK R,KONGTHAI P,LEUNGTONGKAM U,et al. Distribution of virulence genes involved in biofilm formation in mul-ti-drug resistant Acinetobacter baumannii clinical isolates [J]. Int Microbiol,2016,19( 2):121-129.
[23]唐婕.鲍曼不动杆菌临床株耐药、毒力特征及其与Abal/AbaR群体感应系统相关性研究[D].吉林:吉林大学,2019.
[24] KIM M,PARK J,PARK W. Genomic and phenotypic analyses of multidrug-resistant Acinetobacter baumannii NCCP 16007 isolated from a patient with a urinary tract infection[J]. Virulence,2021,12(1):150-164.
[25] BAI B,EALES B M,HUANG W,et al. Clinical and genomic analysis of virulence-related genes in bloodstream infections caused by Acinetobacter baumannii[J]. Virulence,2022,13( 1):1920-1927.
[26] WONG D,NIELSEN T B,BONOMO R A,et al. Clinical and patho-physiological overview of acinetobacter infections:a century of chal-lenges[J]. Clin Microbiol Rev,2017,30( 1):409-447.
[27] GAO Y,LIN H,XU Y,et al. Prognostic risk factors of carbapenem-resistant gram-negative bacteria bloodstream infection in immuno-suppressed patients:a 7-year retrospective cohort study [J]. Infect Drug Resist,2022,15:6451-6462.
[28] LAW S K K,TAN H S. The role of quorum sensing,biofilm forma-tion,and iron acquisition as key virulence mechanisms in Acineto-bacter baumannii and the corresponding anti-virulence strategies[J]. Microbiol Res,2022,260:127032.
[1]文晓龙,权 伟,江荣才.神经外科重症监护室中脑外伤感染泛耐药鲍曼不动杆菌12例分析[J].天津医科大学学报,2015,21(03):255.
[2]余 倩,胡志东,李 静,等.3种方法评估肺炎克雷伯菌及鲍曼不动杆菌对替加环素的体外药敏结果分析[J].天津医科大学学报,2015,21(06):510.
YU Qian,HU Zhi-dong,LI Jing,et al.Effect of Tigecycline on Klebsiella pneumoniae and Acinetobacter baumanaii by susecptibility testing in vitro[J].Journal of Tianjin Medical University,2015,21(04):510.
[3]张 燕,何新飙.ICU患者感染鲍曼不动杆菌的危险因素及耐药性分析[J].天津医科大学学报,2016,22(04):318.
ZHANG Yan,HE Xin-biao.Analysis of risk factors and drug resistance of the patients fected with Acinetobater baumanii in intensive care unit[J].Journal of Tianjin Medical University,2016,22(04):318.
[4]翟慧群,班 博.鲍曼不动杆菌感染对气管插管患者预后的影响[J].天津医科大学学报,2016,22(04):335.
[5]包佳婷,王勇强,王 兵,等.2014-2017年我院鲍曼不动杆菌分布及ICU内鲍曼不动杆菌耐药性分析[J].天津医科大学学报,2019,25(06):600.
BAO Jia-ting,WANG Yong-qiang,WANG Bing,et al.Analysis on the distribution of Acinetobacter baumannii in our hospital and the drug resistance of Acinetobacter baumannii in ICU from 2014 to 2017[J].Journal of Tianjin Medical University,2019,25(04):600.
[6]孔海芳,胡志东.碳青霉烯耐药鲍曼不动杆菌的临床特征及克隆变迁[J].天津医科大学学报,2020,26(05):471.
KONG Hai-fang,HU Zhi-dong.Clinical characteristics and clonal dynamics of carbapenem-resistant Acinetobacter baumannii infections[J].Journal of Tianjin Medical University,2020,26(04):471.